Year: 2025

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : August 20th, 2025Issuer Name Issuer code Transactiondate ISIN Code Daily total volume (in number of actions) Daily weighted average price of shares acquired PlatformCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 20.08.2025 FR001400AJ45 448 631 31.1024 euros Over-the-counterIssuer Name Issuer code PSIName Issuer Code Transaction dateISIN Code Unit Price Currency Quantity bought Platform Transaction reference number Buyback objectiveCompagnie Générale des Etablissements Michelin 549300SOSI58J6VIW052 CA-CIB 1VUV7VQFKUOQSJ21A208 20.08.2025 FR001400AJ45 31,1024 Euro 448...

 Amar Family Office and JCDecaux SE announce the purchase of 1.7 million JCDecaux SE shares Paris, August 20, 2025 – Amar Family Office and JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, are pleased to announce the purchase of a block of 1.7 million JCDecaux SE shares. The purchase was made at a price of €14.75 per share, representing a discount of 0.6% compared to the closing price on August 14, 2025, and corresponding to 0.8% of the capital of JCDecaux SE.  As part of this transaction:Amar Family Office, through its subsidiary Holgespar Luxembourg SA, purchased 873,491 shares, representing 0.408% of the company’s capital; JCDecaux SE also purchased 873,491 of its own shares for a total amount of 12.9 million euros, thus increasing its treasury shares to 0.475% of the capital.This...

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics License Application (sBLA) seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications. The FDA extended the review periods after determining that information provided since the completion of a recent inspection of a third-party manufacturer...

MISSISSAUGA, Ontario, Aug. 20, 2025 (GLOBE NEWSWIRE) — goeasy Ltd. (TSX: GSY) (“goeasy” or the “Company”), one of Canada’s leading consumer lenders focused on delivering a full suite of financial services to Canadians with near to non-prime credit scores, is pleased to announce that it closed its previously announced offering of US$450 million aggregate principal amount of senior unsecured notes due 2031 (the “USD Notes”), which was upsized from US$400 million at the initial time of offering, and C$175 million aggregate principal amount of 6.000% senior unsecured notes due 2030 (the “New CAD Notes”, and together with the USD Notes, the “Notes”), which was upsized from C$100 million at the initial time of offering. The New CAD Notes were issued at a price of C$997.50 per C$1,000 principal amount, plus accrued interest from May 15,...

Austin, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) — DBGI Corp. (Ticker: [NASDAQ:DBGI] a publicly traded company specializing in eCommerce and Fashion today announced it will commence trading on The Nasdaq Capital Market (“Nasdaq”) under its current ticker symbol “DBGI” on Wednesday, August 20, 2025. The uplisting to Nasdaq marks a key milestone in the Company’s evolution, designed to enhance investor visibility, increase liquidity, and allow Digital Brands Group to pursue its growth strategy. The Company believes this transition positions it well to continue building long-term value for shareholders. Digital Brands Group will continue to operate under its current business model and will retain its ticker symbol “DBGI” on Nasdaq. About Digital Brands Group We offer a wide variety of apparel through numerous brands on a both...

CEO positioning VENU as a next-gen Entertainment Powerhouse that expects to, in a few years, sell over 20M tickets annually, driving $2B in volume DENVER, Aug. 20, 2025 (GLOBE NEWSWIRE) — 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that VENU (NYSE American: VENU), a trailblazer in premium hospitality and live entertainment, will launch a digital, blockchain-powered platform in early 2026, designed to expand its entertainment ecosystem far beyond the stage and into the hands, homes, and dashboards of music fans everywhere. The platform will introduce tokenized digital memberships, fan rewards, and soft ticketing services, marking VENU’s entry into the fast-emerging world of real-world asset (RWA) tokenization. The technology will leverage...

LITTLE ROCK, Ark., Aug. 20, 2025 (GLOBE NEWSWIRE) — Uniti (NASDAQ: UNIT), a premier insurgent fiber provider dedicated to enabling mission-critical connectivity across the United States, has been named the #1 Military Friendly® Company for 2025 in the $1 billion-to-$5 billion annual revenue category by VIQTORY Media. Uniti, segments of which were formerly Windstream, was recognized as an employer that goes above and beyond to create meaningful career paths, support, and community for military service members, veterans, and their families. “Uniti is honored that our commitment to hiring and retaining military veterans continues to receive such prestigious accolades,” said Jennifer Ragsdale, executive vice president, chief people and administrative officer. “Veterans and their spouses play a vital role in our mission to deliver mission-critical...

(In United States dollars, except where noted otherwise) TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) — First Quantum Minerals Ltd. (“First Quantum” or the “Company”) (TSX: FM) today announced the early results of its previously announced offer to purchase for cash (the “Tender Offer”) its outstanding 9.375% Senior Secured Second Lien Notes due 2029 (the “Notes”) in a maximum aggregate principal amount of up to $250,000,000 (the “Maximum Tender Amount”), as further described in the offer to purchase dated August 6, 2025 (the “Offer to Purchase”) and as previously announced on August 6, 2025. As of 5:00 p.m., New York City time, on August 19, 2025 (such time, the “Early Tender Time”), according to information provided by Kroll Issuer Services Limited, the tender and information agent for the Tender Offer, the aggregate principal amount...

LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy (“DMD”). “Receiving Orphan Drug designation for KER-065 highlights the significant unmet medical need for patients with DMD,” said Jasbir S. Seehra, President and Chief Executive Officer. “This designation serves as a significant milestone for Keros as we advance KER-065 into a Phase 2 clinical trial in patients with...